Texas: 9 companies selected to expand access to medical cannabis

Texas has granted preliminary approval to nine new companies that could join the Texas market for medical marijuana, one of the most strictly regulated in the country, as part of the Texas Compassionate Use Program (TCUP).

If these operators pass the final audit phase imposed by the State, they will join the three current licensees in a programme of regularly criticized for its restricted access, its limited offering and particularly slow development since its creation ten years ago.

This breakthrough is the result of of a major reform adopted earlier this year, designed to improve access for 116,000 to 127,000 patients registered. This range varies according to official communications, but illustrates the rapid increase in the number of beneficiaries. Until now, TCUP has relied on just three companies authorized to cultivate, produce and distribute cannabis-based treatments.

Under the new regulatory framework, the French government now provides for up to 15 approved distribution organizations to cover the whole of Texas. Monday's announcement brings this total to 12, while three more conditional licenses are expected by April 2026.

A long-awaited expansion for patients

Although selected, none of the 9 companies is yet authorized to cultivate or distribute cannabis products. Each of them must undergo further checks for criminal record, financial solvency and regulatory compliance.

For existing TCUP operators, this expansion marks a turning point. Nico Richardson, CEO of Texas Original, welcomed the announcement, saying: «Thanks to these new licenses, the expanded list of eligibility conditions and the new treatment options authorized by [the new law], patients benefit from a wider choice (new formulations, constant dosage and better administration methods) and can get the care they need.»

The legislative package behind this expansion also introduces higher permitted THC concentrations, authorizes inhalers and vaporizers as methods of administration, and allows the creation of additional storage and retail sites.

At the same time, legislators have broadened eligibility criteria to include chronic pain, chronic Crohn's disease and other problems such as irritable bowel syndrome, head trauma, cancer and post-traumatic stress disorder.

For many patients, this development could finally offer regulated options in a market where thousands of people have turned to cannabinoids derived from hemp, often unregulated and inconsistently dosed. As Goodblend's Nicholas Fallon points out, «widening access to regulated medical cannabis is more important than ever».